• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Gene Watch - Product Image

Gene Watch

  • Published: September 2014
  • Region: Global
  • Council for Responsible Genetics

FEATURED COMPANIES

  • 23andMe
  • GlaxoSmithKline
  • Monsanto
  • Myriad Genetics
  • Navigenics
  • MORE

GeneWatch is America's first and only magazine dedicated to monitoring biotechnology's social, ethical and environmental consequences. Since 1983, GeneWatch has covered a broad spectrum of issues, from genetically engineered foods to biological weapons, genetic privacy and discrimination, reproductive technologies, and human cloning.

While the field of biotechnology holds the potential for dramatic progress in the future, it is also full of misinformation and exaggerated claims. Indeed, biotechnology presents profound national and global policy concerns as well; including the potential impact of scientific developments on human rights and public health. Now, more than ever, there is the need for a strong, independent watchdog.

Countries covered include: the United Kingdom, Canada, countries within the EU, Australia & India.

This GeneWatch subscription provides 5 to 6 magazines annually.

Volume 24 Issue 1: Biobanks; Feb-Mar 2011

Time to Raise Some Hell By Henry T. Greely

Suspect Creatures By CRG staff - with George Annas, Robert Green, Patricia Roche and Susan Wolf

The Harm of Hype By CRG staff - interview with James Evans

UK Biobank: The Grand Experiment By Helen Wallace

From the Cradle to the Lab By Samuel W. Anderson

Book Review: Ethical Issues of Human Genetic Databases By Andrew D. Thibedeau

Case in Point: The NIH’s Biobank Breach By CRG Staff

Genetic Privacy Worries on the Rise By CRG staff - interview with Christy White, Cogent Research

Re-lighting the Beacon By Steve May

GM Alfalfa: An Uncalculated Risk By Philip Bereano

Topic Update: Direct-to-Consumer Genetic Testing Criticized at FDA Hearing By CRG Staff

Editorial By Samuel W. Anderson

Since 1983, the Council for Responsible Genetics (CRG) has represented the public interest and fostered public debate about the social, ethical and environmental implications of genetic technologies. It is the only biotech public interest organization that is explicitly dedicated to examining the best science, interpreting the results, assessing the implications, communicating them to a general audience and facilitating meaningful, measurable change.

CRG continues to carry out these functions through the creation of coalitions of scholars and advocates; translation of scientific and policy analyses into clear and accessible terms for the public, social justice advocates, legislators and the media; and by providing an international, science based source of credible, trusted, current and reliable information on the impacts and implications of developments in biotechnology. Its staff and Board members regularly assist policy makers and have testified before Congress, Federal agencies, regulatory bodies and state legislatures.

The Council for Responsible Genetics is a leader in the movement to steer biotechnology toward the advancement of public health, environmental protection, equal justice, and respect for human rights through lasting policy reform in the United States and around the world.

- GlaxoSmithKline
- 23andMe
- Navigenics
- Myriad Genetics
- Monsanto

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos